Filing Analysis
Neurogene Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2026, and provided an updated corporate presentation.
📋 Key Facts
- The filing reports earnings for the second quarter of 2026 (ended June 30, 2026).
- The Company issued a press release regarding financial results on August 11, 2026.
- An updated corporate presentation was released via the company website.
Neurogene Inc. entered into an underwriting agreement to conduct a public offering of 3,500,000 shares of common stock and up to 666,666 pre-funded warrants at approximately $30.00 per share. The offering is expected to raise approximately $134.8 million in net proceeds.
🚩 Red Flags
- Significant dilution: Issuance of over 4 million new shares (including option exercise) will dilute existing shareholders.
📋 Key Facts
- Offering size: 3,500,000 common shares and up to 666,666 pre-funded warrants.
- Pricing: $30.00 per share; Pre-Funded Warrants priced at $29.999999.
- Underwriters: Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC.
- Expected net proceeds: Approximately $134.8 million (including full exercise of the over-allotment option).
- The underwriters exercised their 30-day option for an additional 624,999 shares on July 1, 2026.
- Management expects proceeds and existing cash to fund operations into Q1 2029.
Neurogene Inc. announced positive updated clinical data from its Phase 1/2 trial of NGN-401 gene therapy for treating females with Rett syndrome. The company issued a press release and corporate presentation to detail these results.
📋 Key Facts
- Announced positive, updated clinical data from Phase 1/2 trial of NGN-401.
- The trial evaluates NGN-401 gene therapy for the treatment of females with Rett syndrome.
- Company hosted a conference call and webcast on June 29, 2026, to discuss results.
Neurogene Inc. announced the completion of dosing in the Embolden™ registrational trial of NGN-401 for the treatment of Rett syndrome. The company also updated its corporate presentation on its website.
📋 Key Facts
- Completion of dosing in the Embolden™ registrational trial for NGN-401 (Rett syndrome treatment) announced on June 8, 2026.
- Updated corporate presentation published on the company website on June 8, 2026.
- The filing consists of furnished information under Item 7.01, meaning it is not officially 'filed' for Section 18 liability purposes.
Neurogene Inc. reported the voting results from its 2026 Annual Meeting of Stockholders held on June 3, 2026. The meeting saw a quorum with 72.92% of voting power present, resulting in the election of two directors and the ratification of the company's auditor.
📋 Key Facts
- Annual Meeting held on June 3, 2026.
- Quorum established with 11,387,407 shares present (72.92% of voting power).
- Robert Baffi and Rohan Palekar were elected as Class III directors to serve until 2029.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026.
- Stockholders voted overwhelmingly (10,006,265 shares) to hold advisory votes on executive compensation every one year.
Neurogene Inc. announced its financial results for the first quarter ended March 31, 2026, and released an updated corporate presentation. This is a routine quarterly disclosure of operations and financial condition.
📋 Key Facts
- Financial results for the quarter ended March 31, 2026, were announced on May 12, 2026.
- The company furnished a press release as Exhibit 99.1.
- An updated corporate presentation was furnished as Exhibit 99.2.
- The report was signed by Christine Mikail, President and Chief Financial Officer.
Neurogene Inc. announced the expansion of its Board of Directors to seven members and the appointment of its current President and CFO, Christine Mikail, to the Board. Additionally, the company announced the hiring of Christina Shafer as Chief Commercial Officer.
🚩 Red Flags
- Multiple 8-K items (5.02 and 7.01) included in a single filing.
📋 Key Facts
- The Board of Directors was expanded from six to seven members effective April 20, 2026.
- Christine Mikail, the Company's President and CFO since 2023, was appointed as a Class II director with a term expiring in 2028.
- Christina Shafer was appointed as the new Chief Commercial Officer.
- Ms. Mikail will not receive additional compensation for her service as a director.
- Ms. Mikail previously held senior roles at Axovant Sciences, NPS Pharmaceuticals, and Eli Lilly and Company.
Neurogene Inc. announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The company also released an updated corporate presentation for investors.
📋 Key Facts
- Financial results cover the period ended December 31, 2025.
- The report was filed on March 24, 2026.
- An updated corporate presentation was furnished as Exhibit 99.2.
- The filing was signed by Christine Mikail, President and Chief Financial Officer.
Neurogene Inc. announced that its investigational gene therapy, NGN-401, has received Breakthrough Therapy Designation from the FDA for the treatment of Rett syndrome.
📋 Key Facts
- The FDA granted Breakthrough Therapy Designation (BTD) to NGN-401 on February 26, 2026.
- NGN-401 is a gene therapy currently in late-stage clinical development for Rett syndrome.
- The announcement was made via a press release furnished under Item 7.01 (Regulation FD Disclosure).
- BTD is designed to expedite the development and review of drugs for serious or life-threatening conditions.
Neurogene Inc. issued a press release and updated its corporate presentation to provide recent corporate updates and anticipated milestones for 2026.
📋 Key Facts
- Filed on January 12, 2026.
- Issued a press release (Exhibit 99.1) regarding corporate updates and upcoming milestones.
- Updated its corporate presentation (Exhibit 99.2) on the company website.
Neurogene Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025. The filing includes a press release and an updated corporate presentation.
📋 Key Facts
- Report date: November 13, 2025
- Reporting period: Quarter ended September 30, 2025
- The company issued a press release (Exhibit 99.1) regarding financial results.
- The company updated its corporate presentation on its website (Exhibit 99.2).
Neurogene Inc. issued a press release and corporate presentation regarding positive interim clinical data from its Phase 1/2 trial of NGN-401 for Rett syndrome in the pediatric cohort (ages 4-10). The filing is a Regulation FD disclosure intended to provide updated clinical progress.
📋 Key Facts
- Announcement date: November 12, 2025
- Clinical Trial Stage: Phase 1/2 trial evaluating NGN-401 gene therapy
- Target Indication: Rett syndrome (females)
- Cohort Specifics: Pediatric cohort (ages 4-10) interim data
- Data Nature: Positive, updated interim clinical data reported
Neurogene Inc. announced a significant clinical milestone regarding its NGN-401 program for Rett syndrome. The company has successfully dosed the first patient in the Embolden™ registrational trial.
📋 Key Facts
- Dosed the first patient in the Embolden™ registrational trial of NGN-401 on November 6, 2025.
- The clinical program targets the treatment of Rett syndrome.
- Company updated its corporate presentation to include enrollment and dosing updates for the Embolden trial.
Neurogene Inc. announced the completion of discussions with the FDA regarding its registrational trial protocol and plans to dose the first participant in Q4 2025. The company also released preclinical data suggesting superior drug delivery via intracerebroventricular (ICV) administration compared to intrathecal lumbar (IT-L) for Rett syndrome.
📋 Key Facts
- Completed discussions with the FDA on registrational trial protocol.
- First participant dosing in the anticipated registrational trial is planned for Q4 2025.
- Preclinical data presented at ESGCT Annual Congress shows ICV administration is superior to IT-L in reaching key brain regions for Rett syndrome.
- Updated corporate presentation released on October 9, 2025.
Neurogene Inc. filed an 8-K to announce its quarterly financial results for the period ending June 30, 2025 and provided an updated corporate presentation.
📋 Key Facts
- Company issued a press release announcing financial results for the quarter ended June 30, 2025 on August 11, 2025.
- The company posted an updated corporate presentation to its website as part of this filing.
- Financial statements and exhibits were furnished under Item 9.01.
Neurogene Inc. issued a press release and updated its corporate presentation to announce the registrational trial design for the Embolden study of NGN-401 gene therapy, targeting Rett syndrome.
📋 Key Facts
- Announced registrational trial design for the Embolden study on June 30, 2025.
- The study focuses on NGN-401 gene therapy for the treatment of Rett syndrome.
- Updated corporate presentation released via company website.
Neurogene Inc. reported the results of its 2025 Annual Meeting of Stockholders held on June 12, 2025. The meeting resulted in the election of two Class II directors and approval of amendments to equity incentive plans and the ratification of Deloitte & Touche LLP as independent auditors.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on June 12, 2025, with a quorum representing approximately 80.50% of voting power (11,481,532 shares).
- Elected Sarah B. Noonberg and Robert 'Keith' Woods to the Board of Directors through the 2028 annual meeting.
- Stockholders approved amendments to both the 2023 Equity Incentive Plan and the 2023 Employee Stock Purchase Plan regarding share reserve calculations for prefunded warrants and preferred stock conversion.
- Ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Neurogene Inc. filed an 8-K to announce the posting of an updated corporate presentation on its website.
📋 Key Facts
- The company released a new corporate presentation dated June 2025 (Exhibit 99.1).
- Filing date: June 9, 2025.
- The filing is under Item 8.01 (Other Events).
Neurogene Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2025. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Report date: May 9, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes an earnings press release as Exhibit 99.1
- Information under Item 2.02 is furnished but not filed for purposes of Section 18 liability.
Neurogene Inc. entered into an amendment to a side letter with Baker Bros. Advisors LP and simultaneously executed an exchange agreement where existing stockholders exchanged 667,500 common shares for prefunded warrants.
🚩 Red Flags
- Significant potential dilution: The prefunded warrants represent approximately 32% of the current outstanding common stock (6,792,559 / 14,262,066).
- Concentrated ownership/Governance shift: The increase in BBA's nomination threshold suggests a negotiated change in board control rights.
📋 Key Facts
- Amendment to July 17, 2023 letter agreement: BBA's director nomination threshold increased from 12.5% to 14.9% of outstanding voting common stock.
- Exchange Agreement: Existing stockholders exchanged 667,500 shares of common stock for prefunded warrants to purchase 667,563 shares at an exercise price of $0.001 per share.
- The exchange is expected to close on or about April 14, 2025.
- Post-exchange capital structure: 14,262,066 shares outstanding and prefunded warrants for 6,792,559 shares.
- Warrants include a beneficial ownership limitation of 4.99%, with an option to increase up to 19.99% via 61 days' notice.
Neurogene Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2024. The filing includes a press release and an updated corporate presentation.
📋 Key Facts
- Report date: March 24, 2025
- Reporting period: Quarter and Year ended December 31, 2024
- Includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Corporate Presentation)
- Information furnished under Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
Neurogene Inc. filed an 8-K to furnish an updated corporate presentation on its website as part of a Regulation FD disclosure.
📋 Key Facts
- The filing was made on January 13, 2025.
- The company updated its corporate presentation (Exhibit 99.1).
- Information is furnished under Item 7.01 and not filed for purposes of Section 18 liabilities.
Neurogene reported the death of a clinical trial participant in its Phase 1/2 Rett syndrome study due to complications from high-dose AAV exposure. Consequently, the company is adjusting its dosing strategy for both current and future trial cohorts.
🚩 Red Flags
- Serious adverse event (death) in clinical trial participant
- Safety concerns regarding high-dose AAV exposure leading to hyperinflammatory syndrome
- Potential impact on the development timeline and efficacy profile of NGN-401 due to dose reduction
📋 Key Facts
- Participant dosed on November 5 with 3E15 vg of NGN-401 died following a life-threatening hyperinflammatory syndrome.
- The death was associated with systemic exposure to high doses of adeno-associated virus (AAV).
- FDA has permitted the company to proceed with Phase 1/2 trials using a lower dose of 1E15 vg for both pediatric and adolescent/adult cohorts.
- Neurogene will incorporate the 1E15 vg dose into future registrational trial design planning.
Neurogene Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024. The filing serves as a formal mechanism to furnish quarterly earnings data via a press release.
📋 Key Facts
- The company issued a press release on November 18, 2024, regarding financial results for the quarter ended September 30, 2024.
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
- Information provided under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Neurogene Inc. issued an 8-K to provide a clinical update regarding its Phase 1/2 trial of NGN-401 gene therapy for Rett syndrome via a press release.
📋 Key Facts
- The filing is a Regulation FD disclosure (Item 7.01) providing clinical updates.
- Focuses on the Phase 1/2 clinical trial of NGN-401 gene therapy.
- Target indication for the therapy is Rett syndrome.
- Information was furnished under Item 7.01 and not filed as a formal report subject to Section 18 liabilities.
Neurogene Inc. issued a press release and presentation regarding clinical trial updates for its Rett syndrome gene therapy program. The disclosure includes initial efficacy data from the first four participants in the low-dose cohort and updated safety/tolerability data for both low-dose and high-dose pediatric cohorts.
📋 Key Facts
- Released initial efficacy data from the first four participants in the low-dose cohort of the Phase 1/2 Rett syndrome trial on November 11, 2024.
- Provided updated safety and tolerability data for both low-dose and high-dose pediatric cohorts.
- Issued a corporate presentation via webcast to accompany the clinical data release.
Neurogene Inc. entered into a securities purchase agreement to conduct a private placement of common stock and pre-funded warrants, expected to raise approximately $200 million.
🚩 Red Flags
- Significant potential dilution from the issuance of common stock and pre-funded warrants (totaling over 4 million shares).
- Pre-funded warrants allow investors to bypass certain beneficial ownership limitations, potentially concentrating ownership.
📋 Key Facts
- Private placement involves 1,835,000 shares of common stock at $50.00 per share.
- Issuance of pre-funded warrants for up to 2,165,042 shares at a price of $49.999 per warrant (exercise price of $0.0001).
- Expected gross proceeds: approximately $200.0 million.
- Participating investors include RTW Investments, Casdin Capital, EcoR1 Capital, Redmile Group, Great Point Partners, LLC, Commodore Capital, and Samsara BioCapital.
- Closing date expected on November 5, 2024.
- The company will enter into a Registration Rights Agreement to register the securities for resale.
Neurogene Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024 and provided an updated corporate presentation.
📋 Key Facts
- Report date: August 9, 2024
- Reporting period: Quarter ended June 30, 2024
- Included Exhibit 99.1: Press Release regarding financial results
- Included Exhibit 99.2: Updated Corporate Presentation (August 2024)
Neurogene Inc. announced that its gene therapy candidate NGN-401 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for the treatment of Rett syndrome. This designation is based on preliminary clinical evidence from ongoing Phase 1/2 trials.
📋 Key Facts
- NGN-401 received RMAT designation from the FDA for Rett syndrome.
- Designation is based on preliminary clinical evidence from an ongoing Phase 1/2 clinical trial.
- RMAT benefits include early/frequent communication with FDA senior managers and eligibility for Accelerated Approval pathway.
Neurogene Inc. filed an 8-K to furnish an updated corporate presentation on its website as part of a Regulation FD disclosure.
📋 Key Facts
- The filing was made on June 21, 2024.
- The company posted an updated corporate presentation (Exhibit 99.1) to its website.
- Information provided under Item 7.01 is furnished but not 'filed' for purposes of Section 18 liability.
Neurogene Inc. issued a press release regarding clinical trial progress for its NGN-401 gene therapy for Rett syndrome. The company reported that the first patient in Cohort 2 received a high dose which was well tolerated, and updated safety data from low-dose patients showed no new treatment-related adverse events.
📋 Key Facts
- First patient in Cohort 2 of Phase 1/2 clinical trial for NGN-401 (Rett syndrome) received a high dose on or before June 18, 2024.
- High dose was reported as well tolerated to date.
- Updated safety data presented at the International Rett Syndrome Foundation ASCEND 2024 Summit.
- Three patients have previously received low doses of NGN-401 with an overall favorable safety profile and no new treatment-related adverse events.
Neurogene Inc. held its 2024 Annual Meeting of Stockholders on June 14, 2024. The meeting resulted in the election of two directors and the ratification of the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 14, 2024, with a quorum representing ~76.40% of voting power (9,829,572 shares).
- Cory Freedland and Rachel McMinn were elected to the Board as Class I directors through 2027.
- Shareholders approved the compensation of named executive officers on an advisory basis.
- Shareholders ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024.
Neurogene Inc. announced that its NGN-401 gene therapy for Rett syndrome has been selected for the FDA's START Pilot Program, which provides enhanced communication and guidance on clinical trial design.
📋 Key Facts
- NGN-401 is a gene therapy targeting Rett syndrome.
- The FDA's START (Support for Clinical Trials Advancing Rare Disease Therapeutics) Pilot Program was selected by the company.
- Program benefits include frequent advice and ad-hoc conversations regarding clinical study design, control group selection, and patient population fine-tuning.
Neurogene Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2024 and provided an updated corporate presentation.
📋 Key Facts
- Announcement of quarterly financial results for the period ending March 31, 2024.
- Release of an updated corporate presentation via Exhibit 99.2.
- Filing date: May 10, 2024.
Neurogene Inc. issued a press release under Regulation FD regarding clinical trial data presentation at the ASGCT Annual Meeting. The company reported positive initial safety and tolerability data for its NGN-401 gene therapy candidate in Rett syndrome patients.
📋 Key Facts
- Presented Phase 1/2 gene therapy clinical trial data for Rett syndrome at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting.
- NGN-401 gene therapy candidate was reported as 'generally well tolerated' by all three patients dosed.
- Follow-up periods for the three patients were three, six, and nine months.
Neurogene Inc. entered into an Amended and Restated Consulting Agreement with Stuart Cobb Consulting Ltd., the entity through which the company's Chief Scientific Officer, Dr. Stuart Cobb, provides services.
🚩 Red Flags
- Related-party transaction involving a key executive (Chief Scientific Officer).
📋 Key Facts
- Effective date of agreement: April 19, 2024.
- The agreement amends and restates a previous consulting agreement from December 12, 2018.
- Minimum annual consulting fee: $440,000, payable in equal monthly installments.
- Success fee eligibility: Up to 40% of the annualized consulting fee based on Board-determined performance parameters.
- Termination provisions include lump sum payments (1.0x annual fee) and pro-rata success fees if terminated without cause or for good reason.
Neurogene Inc. issued a press release regarding the presentation of initial safety and tolerability data from its Phase 1/2 gene therapy clinical trial for Rett syndrome at the ASGCT Annual Meeting.
📋 Key Facts
- Presented NGN-401 gene therapy candidate data at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting.
- Reported that NGN-401 has been generally well tolerated in patients.
- Stated there were no treatment-emergent or procedure-related serious adverse events (SAEs).
- Observed no signs of MeCP2 overexpression-related toxicity, even in a patient with a mild variant predicted to result in residual MeCP2 function.
Neurogene Inc. announced new executive employment agreements for its CEO, Rachel McMinn, Ph.D., and its President/CFO, Christine Mikail, effective April 1, 2024.
🚩 Red Flags
- None identified; these are standard executive compensation disclosures following leadership appointments/realignments.
📋 Key Facts
- Dr. Rachel McMinn (CEO) annual base salary: $595,000 with a 55% target performance bonus.
- Christine Mikail (President and CFO) annual base salary: $515,000 with a 45% target performance bonus.
- Both executives are eligible for equity-based awards as determined by the Board.
- Employment agreements include specific severance provisions in the event of termination without cause or resignation for good reason, including enhanced payouts if occurring near a change in control.
Neurogene Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023. The filing serves as a formal announcement of the company's annual earnings release.
📋 Key Facts
- Report date: March 18, 2024
- Reporting period: Year ended December 31, 2023
- The filing includes Exhibit 99.1 containing the full press release of financial results.
- Information is furnished under Item 2.02 and not filed for purposes of Section 18 liability.
Neurogene Inc. issued a press release regarding clinical trial updates for its NGN-401 gene therapy program targeting Rett syndrome in female pediatric patients. The filing also includes an updated corporate presentation.
📋 Key Facts
- Announced expansion of the Phase 1/2 clinical trial for NGN-401.
- Trial focus: Female pediatric patients with Rett syndrome.
- Updates aimed at enabling more rapid enrollment in the clinical trial.
- Published an updated corporate presentation on March 4, 2024.
Neurogene Inc. announced the appointment of Donna Cochener as Senior Vice President and General Counsel, effective February 15, 2024. Ms. Cochener previously served in interim leadership roles during the company's recent merger transition.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Appointment of Donna Cochener as SVP and General Counsel on February 15, 2024.
- Base salary for 2024 is set at $370,000 per annum.
- Annual performance bonus eligibility up to 35% of base salary.
- Option grant of 40,000 shares with a 4-year vesting schedule (25% at one year, remainder monthly over 36 months).
- Termination of her prior consulting agreement by mutual agreement as of the hire date.
Neurogene Inc. issued a press release regarding business updates and its outlook for the 2024 fiscal year. The filing also includes an updated corporate presentation.
📋 Key Facts
- Company issued a press release on January 5, 2024, detailing business updates and 2024 outlook.
- Updated corporate presentation was posted to the company website on January 5, 2024.
- Information is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.